AKT1 and neoplasm: The DDIT4-mediated inhibition of the PI3K-Akt/mTOR pathway may modulate the TIME through multiple mechanisms, and a comprehensive understanding of these regulatory pathways could provide valuable insights for optimizing the precision and efficacy of tumor immunotherapy.